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1. Introduction  28 
Sirolimus (SRL), also known as rapamycin, is an immunosuppressive agent commonly 29 
administered to renal transplant recipients since it is associated with less long-term nephrotoxicity 30 
than calcineurin inhibitors (CNIs).[1]  31 
SRL has been shown to be a highly effective immunosppressive drug in preventing renal allograft 32 
rejection; nevertheless it may promote the occurrence of different adverse effects, most commonly 33 
hyperlipidemia and myelosuppression.[1] In addition, post-marketing surveillance revealed a number 34 
of unpredicted adverse effects, among which the occurrence of thrombotic events [2, 3] and acute 35 
thrombotic microangiopathy (TMA).[4] 36 
Here we report the case of a renal transplant recipient who developed de novo biopsy-proven 37 
systemic TMA and deep venous thrombosis following treatment with SRL. 38 
2. Observation  39 
A 65-year-old Caucasian male, with a history of left kidney nephrectomy for renal cell carcinoma 40 
(1999), developed end-stage renal disease due to progressive hypertensive nephrosclerosis on 41 
residual multicystic dysplastic kidney. The patient was maintained on hemodialysis for nearly 3 42 
years prior to receiving a cadaveric renal transplant in June 2011. Initial immunosuppression 43 
therapy consisted of mycophenolate mofetil (MMF), tacrolimus and prednisone. Patient also 44 
 
 
received valacyclovir and co-trimoxazole for prophylaxis against cytomegalovirus and 45 
Pneumocystis jirovecii respectively. In December 2011 tacrolimus treatment was switched to SRL 46 
to avoid the long-term nephrotoxicity related to CNIs and in consideration of patient’s history of 47 
malignant neoplasm. At the end of January 2012 patient reported pain, swelling, warmth and 48 
redness of the left leg of some days’ duration. A deep venous thrombosis of soleal veins was 49 
diagnosed by color Doppler and anticoagulant therapy was prescribed. Anticoagulant therapy 50 
consisted of subcutaneous low-molecular-weight heparin (enoxaparin) followed by warfarin, with 51 
the target being the international normalized ratio of 2.5. At the same time a hypercoagulability 52 
state was explored but thrombophilia screening (factor V Leiden mutation, antithrombin III, protein 53 
C, protein S and antiphospholipid antibodies) was normal. Two weeks later, in concomitance with 54 
routine examinations, a mild proteinuria was observed. Proteinuria progressively increased, 55 
reaching nephrotic range (5g/24 hours) at the end of March with hypoalbuminemia (30 g/L) 56 
associated to a rise in weight of about 30 kg due to lower limb edema. Moreover serum creatinine 57 
gradually rose from 1.7 mg/dl to 3.4 mg/dl, consequently a renal allograft biopsy was performed. 58 
Based on histologic findings (figure 1), the patient was diagnosed with TMA which was not related 59 
to transplant rejection in the absence of C4d deposition and circulating donor-specific anti-HLA 60 
antibodies. 61 
In the same days the patient complained of abdominal pain and hematochezia: a subsequent 62 
colonoscopy revealed a severe ischemic pancolitis mo t likely related to TMA (figure 2). Colon 63 
biopsies confirmed the diagnosis of TMA and histological findings included capillary thrombosis 64 
and perivascular hemorrhages. 65 
During the evolution of the disease, there were no laboratory signs of mechanical hemolytic 66 
anemia: lactate dehydrogenase, bilirubin and haptoglobin values were stable and in the normal 67 
range and there was no schistocytosis. Platelet count was within normal limits and SRL levels were 68 
not significantly elevated (in the range of 5 to 7 ng/ml) before or at the time of the diagnosis of 69 
TMA. Since previous reports have suggested a relationship between SRL and TMA, treatment with 70 
 
 
SRL was discontinued and replaced with belatacept. Prednisone and MMF were continued. This 71 
resulted in a rapid and sustained improvement of the clinical picture and a progressive 72 
normalization of laboratory values; patient's serum creatinine decreased to 2 mg/dl and proteinuria 73 
to 2g/24 hours. 74 
 75 
 76 
3. Discussion  77 
SRL is a potent immunosuppressive drug used for the prevention of allograft rejection after solid 78 
organ transplantation.[1] SRL exerts its biologic effects by inhibiting the mammalian target of 79 
rapamycin (mTOR), a cytosolic protein kinase that regulates angiogenesis, protein synthesis and 80 
cell growth, proliferation and survival. The immunosuppressive effect of SRL is related primarily to 81 
its ability to interfere with IL-2–mediated T-cell proliferation that is critical in cell-mediated 82 
immune response.[1, 5] Furthermore SRL exerts direct immunosuppressive effects on other immune 83 
cells such as antigen-presenting cells, B cells, Natural Killer cells and neutrophils.[5] mTOR 84 
inhibitors have also strong anti-proliferative effect on non-immune cells such as fibroblasts, 85 
vascular smooth muscle cells, endothelial cells and various tumor cells. Consequently SRL, as well 86 
as other mTOR inhibitors (e.g. everolimus, temsirolimus), are being tested extensively for several 87 
pathologies including malignancies (e.g. renal cellarcinoma, neuroendocrine tumors, lymphoma, 88 
breast cancer and melanoma and non-melanoma skin cancers), cardiovascular diseases, tuberous 89 
sclerosis and lymphangioleiomyomatosis.[2, 6] 90 
Although SRL has been shown to be a highly effectiv immunosuppressive drug in solid organ 91 
transplantation, it has several adverse effects. The most common adverse effects of sirolimus are 92 
thrombocytopenia, leukopenia, hypertriglyceridemia and hypercholesterolemia.[1] Recent data 93 
suggest that the use of SRL is associated with an increased risk of thrombotic events[2, 3] and 94 
TMA. [4] 95 
 
 
TMA is a rare but severe disease caused by an endothelial injury that results in thrombosis in 96 
capillaries and arterioles. It may be seen in associati n with thrombocytopenia, variable degrees of 97 
microangiopathic hemolytic anemia and organ ischemia.[7] TMA is a well-known serious 98 
complication of renal transplantation and the majority of TMA cases observed after renal 99 
transplantation are related to CNI therapy. Infections, severe renal ischemia and acute humoral 100 
rejection are less frequent causes of TMA. According to a large historical cohort study the incidence 101 
of TMA in renal transplant recipients is 4.9 episodes per 1,000 person-years for de novo TMA.[8] 102 
The clinical picture of post-transplantation TMA is pleomorphic: systemic TMA manifests itself 103 
with renal failure, hemolytic anemia and thrombocytpenia while localized TMA’s clinical 104 
manifestations include worsening renal function, or delayed graft function, with few or no systemic 105 
manifestations, thrombocytopenia and anemia. However localized or systemic TMA represent 106 
different ranges of severity of the same syndrome that may initially present as localized but 107 
successively evolve to systemic disease.[7, 9] 108 
In our report the close chronological relationship between the development of deep venous 109 
thrombosis, renal TMA and ischemic colitis and the onset of treatment with SRL together with the 110 
prompt and persistent improvement of the clinical picture following suspension of the drug strongly 111 
suggest its causal role in the development of these events. In addition, our patient did not have a 112 
history of TMA and, at the time of the events, the patient was administered no other medication 113 
known to cause iatrogenic TMA or a prothrombotic state. On the other hand we did not detect dose-114 
dependent toxicity since SRL blood concentrations were always within normal range. In this setting 115 
renal biopsy was most likely the only modality to recognize TMA in our SRL-treated patient.  116 
The incidence of proteinuria has been recently report d among patients on SRL-based therapy and 117 
attributed to direct SRL toxicity on recipient kidney. This increased proteinuria has been attributed 118 
to proximal tubular cell injury or de novo focal segmental glomerulosclerosis probably induce by a 119 
direct podocyte injury.[10-12] In this context kidney biopsy showing only TMA typical lesions, 120 
permitted to exclude other forms of SRL-induced kidney toxicity on tubular or glomerular 121 
 
 
structures. In our patient hypoalbuminemia was relatively modest (30 g/L) therefore it can hardly 122 
explain the massive weight increase (30 kg) and periph al edemas observed. One explanation for 123 
this finding is that the patient could have developd a simultaneous capillary leak syndrome, as 124 
previously reported in patients treated with SRL for psoriasis.[13]  125 
Although it is still unclear how SRL can trigger TMA, it is possible that the drug decrease VEGF 126 
production and induce endothelial damage leading to platelet aggregation, thrombosis and, 127 
consequently, tissue ischemia.[4, 14] A similar pathogenic mechanism, in particular endothelial 128 
toxicity, could also explain the increased incidence of venous thrombosis observed in patients 129 
treated with SRL.[2, 3] 130 
In summary, systemic TMA and venous thrombosis are em rgent adverse effects of SRL as its 131 
therapeutic applications increase; therefore clinicia s should beware of these potentially life-132 
threatening complications.  133 
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Figure 1. Kidney biopsy (Masson's trichrome stain) showed mesangial proliferation with 179 
mesangiolysis (panel A), thickening of the capillary wall and a glomerular capillary occluded by a 180 



















Figure 2. The findings at colonoscopy showed segmental erythema and congestion interspersed 198 
with areas of normal mucosa. No ulcerations or macroscopic bleeding were observed (panel A: left 199 
colon; panel B: right colon). Terminal ileum and rectum appeared free from disease. 200 
